About dawnThis author has not yet filled in any details.
So far dawn has created 28 blog entries.
Roger Greenhalgh (top left), Armando Mansilha (top middle), Manj Gohel (top right), Christopher Cheng (bottom left), Michael Jolly (bottom middle), and Houman Jalaie (bottom right)
A poll of an enthused audience of venous specialists during the CX 2020 LIVE Deep Venous Disease Consensus […]
Michele Antonello (top) chairs the discussion, following the Industry Symposium, with Amer Zanabili and Bella Huasen.
The CX Innovation Programme showcased technological developments happening in all areas of the Charing Cross Symposium: acute stroke, aortic, peripheral, venous, vascular access, and wound care. Additionally, a new “Dragons’ Den” winner was crowned.
In the first talk of the session, Lindsay Machan (Vancouver, Canada) talked about the lessons he had learnt from being a founder […]
The first-ever 60-month data on Medtronic’s VenaSeal closure system were presented on Tuesday, indicating that at five years, treatment with the cyanoacrylate adhesive for closure of diseased vein segments was not inferior to the alternative treatment arm of radiofrequency ablation (RFA). Nick Morrison of […]
Abstract Submissions for CX 2020 are now closed
The CX Abstract Board is calling for senior and trainee doctors in the vascular and endovascular field to submit their abstracts for presentation at the Charing Cross Symposium (21–24 April 2020, London, UK).
The best abstract presentation […]
Poster prize winner Wei-Wen Ang with CX Abstract Board and Poster member Anna Prent
At Charing Cross 2018, abstracts were presented—across 17 sessions—on the five programme areas of CX: Acute stroke, Thoracic Aortic Abdominal Aortic, Peripheral, Venous, and Vascular Access. Additionally, throughout the symposium, delegates […]
One-year outcomes of EndoAnchor study adds ESAR—endosuture aneurysm repair—to the endovascular lexicondawn2018-04-27T10:01:22+01:00
Frank Arko (Charlotte, USA) presented one-year results from the 70-patient short-neck cohort of the ANCHOR Registry. Patients were treated with an endograft and endoanchors (Endurant and Heli-FX, Medtronic) for abdominal aortic aneurysm. The data showed “very good clinical outcomes in a challenging patient population”, Arko […]
A physician-sponsored investigational device exemption trial on thoracic endovascular aortic repair (TEVAR) using a new thoracic stent graft (Valiant thoracoabdominal aortic aneurysm stent graft, Medtronic), along with its initial 30-day data, was revealed at a Podium 1st presentation at CX 2018 by Thomas Maldonado (New York, USA). […]
CX delegates were presented data from the first 10 EVAR patients treated using a new conformable device, the Gore Excluder conformable abdominal aortic aneurysm endoprosthesis with active control system, yesterday.
Robert Rhee (Brooklyn, New York), the national principal investigator of the US investigational device exemption (IDE) trial for […]
In an exciting session yesterday, the CX audience witnessed the demonstration of a novel treatment strategy with intravascular lithotripsy for calcified arterial stenosis. It will now become a CX tradition to feature live cases to showcase what has been discussed in the presentations, so that the audience […]
In yesterday’s plenary programmes, the future of the Charing Symposium was launched with the initiation of live case demonstrations to illustrate key data discussed on the programme. This year, both the Thoracic Aortic programme and the Peripheral Critical Ischaemia programme featured these illuminating cases, which stirred discussion and […]
Stroke is a major concern following TEVAR (thoracic endovascular aortic repair) and Charing Cross delegates heard the results from a collaborative study that pooled practice data from a number of high-volume centres in order to benefit patients undergoing the procedure. A highlight of the session was the […]
The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium yesterday. The presentation was accompanied by simultaneous publication in the New England Journal of Medicine after the session.
The randomised trial revealed that early endovenous ablation outperforms deferred […]
Majority of CX audience decides endovascular-first strategy for critical limb ischaemia is a concept without evidencedawn2018-04-25T10:26:13+01:00
At the CX Great Debate held yesterday, vascular and endovascular surgery titans went head-to-head to debate the contentious topic “Endovascular-first strategy for critical limb ischaemia is a concept without evidence”. Arguing in favour of this motion were current Society for Vascular Surgery (SVS) president Clement […]
Drug-coated balloon is “highly effective and safe” and shows outstanding clinical improvement for patients compared to an uncoated balloondawn2018-04-25T10:49:59+01:00
The 12-month results from the full clinical cohort of the EffPAC randomised controlled trial, were presented for the first time at the CX Symposium yesterday.
Target lesion revascularisation at 12 months was 1.3% (vs 17.7% in the plain angioplasty group, p<0.001). Primary patency at 12 months […]
The BATTLE trial comparing a drug-eluting stent (Zilver PTX, Cook) vs. a bare metal stent (Misago, Terumo) for the treatment of intermediate femoropopliteal lesions has failed to the show superiority of the paclitaxel-coated stent at one-year follow-up. The trial highlights a need for further direct […]
This year, there are four CX Workshops that offer a record number of hands-on workshop opportunities for those technical tips and tricks. The CX Venous Workshop—which has now been running for 10 years—has more than 80 workstations over two days. Last year, a staggering 1,100 people attended this workshop. Located in the Venous City, […]
This year’s annual China Endovascular Course (CEC; 2–5 November, Beijing, China) played host to the first CX@CEC session, in collaboration with the Charing Cross Symposium. Focused on complex aortic disease, this session featured a selection of international and Chinese experts […]
Ross Naylor at CX 2017
CX 2018 will close with the Acute Stroke CONTROVERSIES programme, which Ross Naylor—a member of the CX Programme Organising Board—promises will be a memorable session. The highlight will be five debates that will address a few “sacred cows” that arouse considerable controversy around […]
This year, CX celebrates 40 Years of Looking Forward. In this video, members of the CX Programme Organising Board and the CX Faculty explain why CX is not only unique but also provides vascular education “as it should be”! Register now for CX 2018!
CX 2018: “I believe delegates of CX 2018 should attend this presentation since the information provided by it will change their practice”dawn2019-09-09T09:29:42+01:00
Juan Parodi (San Isidro, Argentina) gives an opening talk at CX 2018 “Reversal of lower extremity intermittent claudication and rest pain by hydration”. Come to CX on Day 1 to see if it as simple as that! Read the interview below for more information.
What are the limitations […]
Fabrizio Fanelli (Florence, Italy), CX Faculty, says that a key point about CX is that it – unlike other meetings – provides opportunities for discussion. He notes that the “active discussion” at the podium is “very important” for what you learn at the meeting. Register for CX 2018!
CX Faculty member Barry Katzen (Miami, United States) discusses how attending CX has affected his clinical practice and how he always is “universally losing” debates at CX! Register for CX 2018!
CX programme organising board member Alun Davies (Imperial College, London, United Kingdom) reviews how CX has changed in the last 24 years that he has been attending the symposium, his most memorable moments, and the one word he would use to describe the meeting. Register for CX 2018!
“One of the great things” about CX, according to CX Faculty member Kathleen Gibson (Bellevue, United States), is that it provides a “global perspective”. She says she “learns more and more” every time she attends. Register for CX 2018!
Rodney White (Torrance, United States), CX Faculty, says that CX has been a “very good forum” for not only new technologies but also how we adapt them to current practice. He notes that CX chairman Roger Greenhalgh has always been at the forefront of the latest developments. Register for CX 2018!